Literature DB >> 25469304

Bacillus Calmette-Guérin therapy-associated granulomatous prostatitis mimicking prostate cancer on MRI: A case report and literature review.

Nicolaie Suditu1, Dragos Negru2.   

Abstract

Granulomatous prostatitis following bacillus Calmette-Guérin (BCG) immunotherapy is a well-known pathological entity, developing following initiation of BCG therapy as a prophylactic measure against the recurrence of non-muscle invasive bladder cancer. In addition, there are certain imaging similarities between granulomatous prostatitis and prostate cancer, including hypoechoic area on transrectal ultrasonography and low T2 signal intensity in some prostate areas on magnetic resonance imaging (MRI). This is the report of a case exhibiting a perfect imaging cross-match between granulomatous prostatitis and potential prostate cancer on repeated MRI exams, adding two supplementary aspects to the already known similarities, namely progressive restricted diffusion and increased contrast enhancement, which are specific to prostate cancer.

Entities:  

Keywords:  bacillus Calmette-Guérin immunotherapy; granulomatous prostatitis; magnetic resonance imaging; prostate biopsy; prostate cancer

Year:  2014        PMID: 25469304      PMCID: PMC4251198          DOI: 10.3892/mco.2014.422

Source DB:  PubMed          Journal:  Mol Clin Oncol        ISSN: 2049-9450


  10 in total

1.  Elevated prostate specific antigen serum levels after intravesical instillation of bacillus Calmette-Guerin.

Authors:  D Leibovici; A Zisman; Z Chen-Levyi; H Cypele; Y I Siegel; S Faitelovich; A Lindner
Journal:  J Urol       Date:  2000-11       Impact factor: 7.450

2.  EAU guidelines on prostate cancer. Part 1: screening, diagnosis, and treatment of clinically localised disease.

Authors:  Axel Heidenreich; Joaquim Bellmunt; Michel Bolla; Steven Joniau; Malcolm Mason; Vsevolod Matveev; Nicolas Mottet; Hans-Peter Schmid; Theo van der Kwast; Thomas Wiegel; Filliberto Zattoni
Journal:  Eur Urol       Date:  2010-10-28       Impact factor: 20.096

3.  Maintenance bacillus Calmette-Guerin immunotherapy for recurrent TA, T1 and carcinoma in situ transitional cell carcinoma of the bladder: a randomized Southwest Oncology Group Study.

Authors:  D L Lamm; B A Blumenstein; J D Crissman; J E Montie; J E Gottesman; B A Lowe; M F Sarosdy; R D Bohl; H B Grossman; T M Beck; J T Leimert; E D Crawford
Journal:  J Urol       Date:  2000-04       Impact factor: 7.450

Review 4.  EAU guidelines on non-muscle-invasive urothelial carcinoma of the bladder: update 2013.

Authors:  Marko Babjuk; Maximilian Burger; Richard Zigeuner; Shahrokh F Shariat; Bas W G van Rhijn; Eva Compérat; Richard J Sylvester; Eero Kaasinen; Andreas Böhle; Joan Palou Redorta; Morgan Rouprêt
Journal:  Eur Urol       Date:  2013-06-12       Impact factor: 20.096

5.  Incidence of granulomatous prostatitis and acid-fast bacilli after intravesical BCG therapy.

Authors:  P D LaFontaine; B R Middleman; S D Graham; W H Sanders
Journal:  Urology       Date:  1997-03       Impact factor: 2.649

6.  Imaging appearance of granulomatous disease after intravesical Bacille Calmette-Guerin (BCG) treatment of bladder carcinoma.

Authors:  Weining Ma; Stella K Kang; Hedvig Hricak; Scott R Gerst; Jingbo Zhang
Journal:  AJR Am J Roentgenol       Date:  2009-06       Impact factor: 3.959

7.  Incidence and treatment of complications of bacillus Calmette-Guerin intravesical therapy in superficial bladder cancer.

Authors:  D L Lamm; P M van der Meijden; A Morales; S A Brosman; W J Catalona; H W Herr; M S Soloway; A Steg; F M Debruyne
Journal:  J Urol       Date:  1992-03       Impact factor: 7.450

8.  Complications of bacillus Calmette-Guerin immunotherapy in 1,278 patients with bladder cancer.

Authors:  D L Lamm; V D Stogdill; B J Stogdill; R G Crispen
Journal:  J Urol       Date:  1986-02       Impact factor: 7.450

9.  Granulomatous prostatitis following bacillus Calmette-Guerin immunotherapy of bladder cancer.

Authors:  R D Oates; M M Stilmant; M C Freedlund; M B Siroky
Journal:  J Urol       Date:  1988-10       Impact factor: 7.450

10.  ESUR prostate MR guidelines 2012.

Authors:  Jelle O Barentsz; Jonathan Richenberg; Richard Clements; Peter Choyke; Sadhna Verma; Geert Villeirs; Olivier Rouviere; Vibeke Logager; Jurgen J Fütterer
Journal:  Eur Radiol       Date:  2012-02-10       Impact factor: 5.315

  10 in total
  3 in total

Review 1.  Sarcoid-like reaction in cases treated by checkpoint inhibitors.

Authors:  Semra Paydas
Journal:  Med Oncol       Date:  2021-02-18       Impact factor: 3.064

Review 2.  The future of PSMA PET and WB MRI as next-generation imaging tools in prostate cancer.

Authors:  Yishen Wang; Joao R Galante; Athar Haroon; Simon Wan; Asim Afaq; Heather Payne; Jamshed Bomanji; Sola Adeleke; Veeru Kasivisvanathan
Journal:  Nat Rev Urol       Date:  2022-07-04       Impact factor: 16.430

3.  Analysis of risk factors for post-bacillus Calmette-Guerin-induced prostatitis in patients with non-muscle invasive bladder cancer.

Authors:  Tae Jin Kim; Young Dong Yu; Sung Il Hwang; Hak Jong Lee; Sung Kyu Hong; Sang Eun Lee; Jong Jin Oh
Journal:  Sci Rep       Date:  2020-06-17       Impact factor: 4.379

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.